• SHRG is committed to providing cost-effective, enterprise-level solutions that address customers’ key operating needs
• Company has applied its background and experience to design quality services that will support an array of companies
• The new platform is a key component of Sharing Services’ strategic plan to diversify revenue streams

In a key announcement, Sharing Services Global (OTCQB: SHRG) has launched its new Shared Services Platform (https://ibn.fm/LXFLQ). The announcement signals the company’s strategic move to offer a variety of services specifically designed to support companies in the direct-selling industry, a space in which SHRG has proven expertise.

“At Sharing Services, our goal is to provide cost-effective, enterprise-level solutions that address our customers’ key operating needs,” said Sharing Services CEO John “JT” Thatch. “Our platform of services incorporates the absolute highest-caliber solutions for the companies we partner with.”

The company has applied its background and experience with direct selling to design a wide range of services that will support an array of companies, from startups to seasoned organizations. These cost-effective, proven solutions include financial and accounting services, global fulfillment and logistics, back-office platforms and mobile applications, commercial insurance services, merchant processing, inventory financing and equity funding, and event planning and merchandising.

In preparing for this significant offering, SHRG has partnered with other industry experts to ensure the platform delivers best-of-class services that meet the expectations of clients and customers. “With our experience starting and operating companies in this industry, we understand the issues and challenges involved in each particular instance and offer solutions to streamline any process, allowing any company to utilize our services on an à la carte basis,” observed SHRG chief financial officer Anthony S. Chan.

The new platform is a key component of Sharing Services’ strategic plan to diversify revenue streams. “It has been in the planning stages for several months, and some of the products and services are up and running now,” said Thatch. “We will be announcing each company or service in the upcoming weeks and will launch additional companies later this coming year.”

Sharing Services’ primary growth strategy is built on focused innovation and creativity. The company is purposefully positioning itself to capture a profitable market share of diverse business models.

For more information, visit the company’s website at www.SHRGInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• China has demonstrated their intension to weaponize access to critical metals, with restrictions on germanium and gallium scheduled for August, and rare earth metals used in permanent magnets could be next
• China accounts for 90% of the gallium and 80% of the germanium supply exports used in the United States and other European countries
• Gallium and germanium are two materials important for the production of semiconductor chips, and China’s control of the market makes it exceedingly difficult for secure production without a North American supply
• Ucore’s RapidSX(TM) technology utilizes similar chemistry to conventional SX and significantly improves the well-established, well-understood, proven conventional SX separation technology preferred by REE producers
• Ucore’s developing North American REE supply chain includes plants in Louisiana, Alaska, and Canada

Gallium and germanium are two materials important for producing semiconductor chips and key ingredients for power electronics chips, Radio Frequency chips, wireless communication, and high-speed signaling – used in applications like electric vehicles, data centers, 5G, radar, GPS, and wireless communications. China accounts for 90% of the gallium and 80% of the germanium supply exports used in the United States and other European countries. The growing tensions between China and countries worldwide have created a growing number of restrictive trade actions from both sides. Most recently, according to a Business Today article, China’s export curbs on gallium and germanium, two important elements for the production of semiconductors, threatens to disrupt the chip supply chain and increase the price of semiconductors and associated products (https://ibn.fm/y2bL4).

The United States is believed to hold the world’s largest germanium mines, but it does not extract the raw material, an expensive process for obtaining the required purity. Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a critical metals separation technology company executing an ESG-centered plan toward establishing a comprehensive North American critical metals supply chain, has developed a transformative commercial-ready technology for separating and purifying critical metals. Ucore intends to deploy its RapidSX(TM) technology in pursuit of a critical metals supply chain independent of China and Western original equipment manufacturers – most notably in the automotive industry and renewable energy.

The global semiconductor market size was valued at $527.88 billion in 2021. The market is expected to grow from $573.44 billion in 2022 to $1.38 trillion in 2029, growing at a CAGR of 12.2%. This growth is attributed to the increased consumption of consumer electronic devices across the globe and the production of electric vehicles (https://ibn.fm/tXEsl).

Although not a new technology, RapidSX(TM) combines the time-proven chemistry of conventional solvent extraction (“SX”) with a new column-based platform that significantly reduces time to completion and plant footprint and potentially lowers capital and operation costs. SX is the international rare earth element (“REE”) industry’s standard commercial separation technology and is currently used by all REE producers worldwide for bulk commercial separation of both heavy and light REEs.

Ucore’s RapidSX(TM) technology utilizes similar chemistry to conventional SX and significantly improves the well-established, well-understood, proven conventional SX separation technology preferred by REE producers. The commissioning of Ucore’s RapidSX(TM) Demonstration Plant is underway in Kingston, Ontario, and is designed to demonstrate the commercial capabilities of its technology. Ucore’s RapidSX(TM) Demonstration Plant will show:

• The techno-economic advantages of the RapidSX(TM) technology platform
• The processing of tens of tons of heavy and light REE concentrates in a simulated production environment
• The platform’s ability to operate for thousands of semi-continuous run-time hours
• Production of high-purity NdPr, praseodymium, neodymium, terbium, and dysprosium rare earth elements for early OEM product qualification trials

The demonstration plant is located within Ucore’s 5,000-square-foot RapidSX(TM) Commercialization and Demonstration Facility run by its laboratory partner, Kingston Process Metallurgy Inc.

By 2025, Ucore expects to commercially separate US-friendly sources of REEs and supply OEMs with REOs required to produce rare earth permanent magnets, essential in electric motors and generators. The company intends to contribute to this initiative through the near-term development of heavy and light REE processing facilities in Louisiana and the subsequent development of Strategic Metals Complexes in Alaska and Canada – as well as a longer-term development of its 100% owned Heavy Rare Earth Element (“HREE”) mineral resource property at Bokan Mountain on Prince of Wales Island, Alaska.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• The global dermatology pharmaceutics market is booming, with increased public awareness and large unmet needs
• BiondVax competitor MoonLake Immunotherapeutics share price jumped 128% after positive findings from a Phase 2 trial evaluating Nanobody(R) sonelokimab in patients with moderate-to-severe hidradenitis suppurativa, a painful long-term dermatological condition
• BiondVax’s NanoAbs address psoriasis and a broad range of other diseases, and with a potentially better safety profile based on administration directly into lesions, rather than MoonLake’s systemic-administration

The global dermatology pharmaceutics market was valued just over $20 billion in 2022 and is expected to surge to nearly $40 billion by 2030, growing at a CAGR of 8.91% during the forecast period (https://ibn.fm/A974K). Dermatology uses pharmaceuticals to control and treat numerous conditions that affect the skin, hair, nails, and more.

BiondVax Pharmaceuticals (NASDAQ: BVXV), an innovative biotechnology company focused on developing, manufacturing, and commercializing potential blockbuster immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is developing a pipeline of unique nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments with large growing markets – including dermatological conditions such as psoriasis.

MoonLake Immunotherapeutics (NASDAQ: MLTX), a BiondVax competitor, recently reported positive results from its Phase 2 clinical trial evaluating Nanobody(R) sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (“HS”), a painful long-term dermatological condition characterized by the occurrence of inflamed and swollen lumps that significantly limit many everyday activities. The MIRA trial (M1095-HS-201) recruited 234 patients and is the first randomized, double-blind, placebo-controlled trial to use Hidradenitis Suppurativa Clinical Response (“HiSCR”) 75 as its primary endpoint, a higher measure of clinical response versus the HiSCR50 measure, which is commonly used in other clinical trials – representing a landmark milestone in the treatment of HS. The result, according to SeekingAlpha, was a stock jump of 128% (https://ibn.fm/Kc1XO).

The biological target of MoonLake’s Nanobody is the human immune system cytokine IL-17. IL-17 is implicated in several diseases. It’s important to remember that MoonLake’s MIRA trial does not pertain to psoriasis but rather to the indication of the orphan disease HS whose market is much smaller. BiondVax is initially targeting IL-17 for treatment of psoriasis, where the market size for therapeutics is expected to reach $44 Billion by 2031. The company’s plan for the IL-17 nanobody also includes addressing diseases like HS, psoriatic arthritis, and other large markets. BiondVax also intends to use IL-17 in mild-to-moderate psoriasis patients, which comprise a higher number of patients compared to the smaller segment of severe patients targeted in a previous MoonLake’s trial.

In addition, unlike MoonLake’s nanobody formulation, BiondVax’s NanoAbs do not require the conjugation of two antibodies with a linker and do not require albumin attachment, making BiondVax’s therapy easier and cheaper to produce. While MoonLake’s nanobody exhibited a favorable safety profile, BiondVax’s therapies are designed to be injected directly into psoriatic lesions, and therefor are expected to provide an even better safety profile than systemic therapies like MoonLake’s.

MoonLake’s success proves how hungry the market has become for nanobody therapies that target IL-17. Moonlake’s market value was $1.8 billion at the end of the Phase 2 trial, a clear indicator that BiondVax has massive potential to grow exponentially.

BiondVax works in collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”), both in Germany, and research teams have verified a strong affinity by the NanoAbs to their biological target molecules and exceptionally high thermostability. These NanoAbs have also demonstrated strong neutralization by several candidates – which BiondVax will continue to explore as it develops its pipeline for various underserved indications.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• McEwen Mining, an asset-rich diversified gold and copper producer that owns a 52% stake in McEwen Copper, recently released the results of an updated Preliminary Economic Assessment (“2023 PEA”)
• The 2023 PEA documented, among others, an updated independent mineral resource estimate and a base case development strategy that is distinctly different from that proposed in the 2017 PEA
• The recent PEA proposes the development of an open pit mine with crushing, heap leaching, and solvent extraction and electrowinning (“SW/EW”) facilities to process the mined materials, producing copper cathodes that meet LME Copper Grade A quality standards
• The updated development strategy is expected to reduce fresh water consumption by ~75%, electricity consumption by ~75%, and greenhouse gas emissions by ~57%
• McEwen Mining is confident that once implemented, the proposal will make the Los Azules copper cathodes attractive to end users looking to measurably reduce their upstream environmental impacts

As industries seek to decarbonize and transition toward net zero, electrification ranks among the top strategies being considered and implemented. A cornerstone of these efforts, copper is garnering interest, with forecasts showing that demand will double to 50 million tons by 2050 from 2020 levels (https://ibn.fm/xprgL). Chief among the drivers is that copper is an essential raw material used to manufacture components and equipment for energy generation and transmission, digital applications, and electronics. In fact, according to Shehzad Bharmal, Chairman of the International Copper Association (“ICA”), “Copper is the catalyst at the heart of the energy transition, with two-thirds of the technologies for decarbonization requiring coppers as a core component” (https://ibn.fm/HcmPs).

In line with the decarbonization efforts and amid the surging demand, some copper producers are working to reduce the environmental impacts of their activities to potentially make themselves and/or their products attractive to environmentally-conscious downstream customers and/or investors. The consciousness around companies’ environmental footprint has also roped in companies like McEwen Mining (NYSE: MUX) (TSX: MUX), an asset-rich diversified gold and copper producer with operations in Nevada, Canada, Mexico, and Argentina, and its 52%-owned McEwen Copper subsidiary.

McEwen Mining recently released the results of an updated Preliminary Economic Assessment (“2023 PEA”) on the 100% McEwen Copper-owned Los Azules Copper Project in San Juan, Argentina, documenting an updated base case development strategy, which is starkly different from that presented in the previous PEA published in 2017, as well as an updated independent mineral resource estimate (https://ibn.fm/mNXPs).

On its part, the 2017 PEA selected a strategy that proposed the construction of a mine with a conventional mill and flotation concentrator that produces a concentrate primarily for export to international smelters. In contrast, the 2023 PEA proposes a Phase 1 implementation strategy that includes the development of an open pit mine with crushing, heap leaching, and solvent extraction and electrowinning (“SW/EW”) facilities to process the mined materials, producing copper cathodes that meet London Metals Exchange (“LME”) Copper Grade A quality standards for sale in Argentina or international markets.

The selection of the updated implementation strategy rode on three primary principles, chief among them the environmental footprint. Compared to the conventional milling and treatment strategy in the 2017 PEA, the proposed heap leach project is set to reduce fresh water consumption by approximately 75% (from 600 to 150 L/s) and electricity consumption by about 75% (from 230 to 57 MW). The updated strategy is also expected to reduce Scope 1 and 2 greenhouse gas (“GHG”) emissions by approximately 57% from 1,560 to 670 CO2e/t Cu. McEwen Copper is also considering paths to further reduce GHG emissions by implementing new technologies, with the goal of reaching net-zero carbon by 2038 with some offsets. One of these paths might be the potential deployment of Nuton(TM), a portfolio of proprietary copper bio-heap leach-related technologies.

Last August, McEwen Copper and Nuton LLC, a Rio Tinto Venture, entered into a collaboration agreement to test the viability of Nuton(TM) (https://ibn.fm/vD2i9). According to the press release announcing the results of the 2023 PEA, Nuton(TM) provides a “significant opportunity to optimize the mine plan and the overall mining and processing operations. In addition, Nuton(TM) provides other significant benefits, such as lower overall energy consumption, allowing earlier conversion to renewable energy sources, and lower water consumption than conventional sulfide mineralization treatment processes.”

However, McEwen Copper does not currently have a commercial agreement with Nuton that sanctions the deployment of the technologies at the Los Azules Project. Still, the two companies intend to work in good faith toward such an agreement, although there is no guarantee that it will come to fruition.

McEwen Copper is nonetheless still positioned to make remarkable progress through the implementation of its proposed strategy, the additional efforts and potential agreement notwithstanding. The company is confident this strategy will make the Los Azules copper cathodes attractive to end users looking to measurably reduce their upstream environmental impacts.

For more information, visit the company’s website at www.McEwenMining.com.

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at http://ibn.fm/MUX

• Starco Brands partners with AMC to offer Whipshots(R) Vanilla or Lime flavors to cocktails at 250+ theatres across the United States
• Partnership to include “Whip It, Beaches” campaign spot before selected films and imagery throughout theaters
• Whipshots earned several awards, including Beverage Dynamics’ 2023 “Rising Star Award”, 2023 SIP Innovation Award, and four medals at the DB & SB Spring Blind Tasting segment of the 2023 Global Spirits Masters Competition
• Starco Brands 2022 year-end financial statements revealed a 1,060% revenue increase to $7.8 million
• Other Starco Brands products include Kobe Bryant’s Art of Sport premium athletic body care line, Skylar hypoallergenic perfumes, Winona Pure(R) air-powered popcorn spray, and the Soylent line of nutrient-enriched food products

Movie fans aged 21 and over can now add a dollop of Whipshots(R) Vanilla or the new limited-edition lime flavor to cocktails at 250+ AMC Theatres nationwide. Developed by Starco Brands (OTCQB: STCB) in partnership with global artist Cardi B, Whipshots is luxury whipped cream enhanced with a 10% premium vodka kick. Also available in mocha and caramel, the wildly popular boozy whipped cream has sold over 2 million cans since 2021, making it one of the largest product launches that year.

“We are thrilled to bring the iconic sense of fun and excitement of Whipshots to AMC Theatres, allowing moviegoers all over the country to celebrate summer and blockbuster movies with Whipshots,” says David Dreyer, Chief Marketing Officer of Starco Brands, Inc. “Having our ‘Whip It, Beaches’ campaign shown on the big screen is a huge milestone for the brand, and we look forward to offering our product to even more audiences.”

“Whip It, Beaches” was launched earlier this summer to Cardi B’s 168+ million Instagram fans with a 30-second video and images showcasing the limited-edition lime flavor in daiquiris, mojitos, and margaritas. The partnership with AMC further celebrates the “Summer of Whipshots” with images throughout the theatres and campaign spots on the big screen before selected films.

Whipshots has lit up social media and gained legions of fans since its launch, receiving 170+ million views for the #whipshotsreview on Tiktok alone. The product has also received significant industry recognition, including the “Rising Star Award” in Beverage Dynamics’ 2023 Growth Brands Awards, the 2023 SIP Innovation Award, and four medals at the DB & SB Spring Blind Tasting segment of the 2023 Global Spirits Masters Competition.

Whipshots is unique, ground-breaking, and truly new – characteristics shared by all products in Starco Brand’s portfolio. Billed as an “invention factory,” the company identifies gaps in eight consumer categories and fills them by either inventing or acquiring novel products with unique attributes that spark excitement and change behaviors. In addition to creating ground-breaking products like Whipshots, the company has pursued an aggressive M&A strategy to acquire iconic brands, resulting in a staggering 1,060% revenue increase to $7.8 million by year-end 2022.

Other products in Starco Brand’s portfolio include The Art of Sport premium athletic body care line co-founded by basketball legend Kobe Bryant, Skylar hypoallergenic perfumes, Winona Pure(R) air-powered popcorn spray, and the Soylent line of nutrient-enriched products, known as the “world’s most perfect food”.

For more information, visit the company’s website at www.StarcoBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to STCB are available in the company’s newsroom at https://ibn.fm/STCB

• Lexaria just released its mid-year update, highlighting its key milestones so far and its objectives going forward, summarized in a recent Zacks update
• Of note was the company’s most ambitious clinical study yet, HYPER-H21-4, along with its growing patent portfolio that now sees six additional patents awarded across Australia, Japan, the U.S., and Canada so far in 2023
• The company also noted its $2 million capital raise back in May, a strong indicator of shareholders’ confidence in the brand, and its efforts to grow its operations
• Lexaria looks to build on the momentum gathered so far, and its management is optimistic that it will achieve its objectives for the 2023 calendar year

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released its mid-year update, marking significant strides both in its research and in creating value for its shareholders. In a report by Zacks Small Cap Research, the company’s critical milestones for the current calendar year were highlighted, from recent publications to awarded patents and capital raised thus far.

Of note was Lexaria’s most ambitious clinical study yet, HYPER-H21-4, a clinical study exploring the potential of the company’s patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of hypertension. Enrollments for the study kicked off in April 2022, with dosing beginning ahead of schedule and completed on July 27th (https://ibn.fm/xxzAj). With the success of this study so far, Lexaria is on track to file an Investigational New Drug application with the U.S. Food and Drug Administration, for DehydraTECH-processed CBD later this year, in addition to tapping into the hypertension treatment market that is estimated to hit $39.5 billion in value by 2030 (https://ibn.fm/UVij4).

Lexaria has also made significant strides in growing its patent portfolio, with its 28th patent worldwide being awarded in late December 2022. Two additional announcements were made in April and June highlighting several global grants, in addition to six patents awarded across Australia, Japan, the United States, and Canada so far in 2023. This goes a long way in strengthening the Lexaria brand, as evidenced by the $2 million capital raise on May 8th.

This capital raise in a public offering saw 2,106,000 units sold at $0.95 per unit, consisting of one share of stock and a warrant with an exercise price of $0.95 per share, offering a five-year term. It showed shareholders’ confidence in the company and its efforts to grow its operations and fulfill its mandate. It was also a show of the company’s growth and future ambitions.

Lexaria also noted significant progress on its nicotine operations, particularly given its receipt of Independent Review Board (“IRB”) approval for its human nicotine study designated NIC-H22-1. Similar progress was made on its Estradiol hormone study, with the recently-concluded animal study HOR-A22-1 demonstrating successful delivery of estradiol and its metabolite estrone using DehydraTECH. These, and more efforts from Lexaria, were recognized in research circles, with eight research paper publications playing a massive role in it.

In a June 22nd press release, Lexaria acknowledged its most recent publication in the International Journal of Molecular Sciences, titled Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study. The publication noted that CBD concentrations were higher in women than men and correlated with the proportion of adipose tissue. The difference in sexes, it noted, was attributed to higher levels of fat tissue in women than men.

Lexaria looks to build on its momentum so far and achieve its objectives for the 2023 calendar year. Its management is optimistic that these goals, and more, will be achieved in the year and that the company will continue to create value for its shareholders while at it.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• First Tellurium in June 2023 successfully uplisted from the OTC Pink Market to the OTCQB Venture Market
• First Tellurium has contracted for IP geophysics on its Deer Horn Project during summer 2023 to develop targets for a drilling program
• The company has engaged consultants to stake additional claims around its Klondike gold-tellurium project in Colorado
• Key applications for tellurium include high efficiency cadmium telluride solar panels, next-gen lithium-ion batteries, semiconductors, thermoelectric devices, phase-change memory chips and low-energy desalination
• The company plans to investigate and acquire other tellurium projects in North America

First Tellurium (CSE: FTEL) (OTCQB: FSTTF) is committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. This objective is anchored by the company’s Deer Horn tellurium-gold-silver-copper project in British Columbia, Canada, and further enhanced by its property option on the Klondike tellurium-gold prospect located in Colorado, USA.

First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in indigenous territory with sustainable exploration potential.

Through its exploration and partnerships with Fenix Advanced Materials, Cheona Metals and IRMA, First Tellurium strives to generate a measurable, beneficial social or environmental impact alongside a financial return. The company conducts a diversified search for metals, working in alliance with indigenous peoples, NGOs, governments and leading metals buyers. First Tellurium believes this is the future of mineral exploration — generating revenue by exploring responsibly and leveraging diverse partnerships.

First Tellurium proudly adheres to, and supports, the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and, in particular, the fundamental proposition of free, prior and informed consent.

The company is headquartered in Vancouver, British Columbia.

Projects

Deer Horn Tellurium-Gold-Silver-Copper Project

Deer Horn is located on 51.33 square kilometers (km) in west-central British Columbia, 36 km south of the prolific Huckleberry copper-molybdenum mine and 135 km southwest of the community of Burns Lake. It is one of few significant tellurium discoveries outside Asia and includes a 2.4 km-long vein system of high-grade gold, silver and tellurium, as well as broader zones of bulk-tonnage gold, silver and tellurium mineralization. The company completed a positive Preliminary Economic Estimate and has began permitting for a 10,000-tonne bulk sample program to advance the project toward mine feasibility. It is North America’s only silver-gold-tellurium property with an NI 43-101 compliant tellurium resource, and it hosts a number of other mineralized targets and zone containing critical metals such as copper, tungsten and zinc.

First Tellurium owns 50% of the property, with an option to acquire up to a 75% interest. The company has engaged Dias Geophysical of Saskatoon, Saskatchewan, to conduct induced polarization (“IP”) geophysics on the Deer Horn Project in summer 2023. The program is designed to help develop drill targets for a subsequent drilling program.

Klondike Gold-Tellurium Project

The Klondike property is located in Saguache County, Colorado, southwest of Buena Vista in the state’s historical mining district. The company reports it has engaged Burgex Mining Consultants of Sandy, Utah, to stake additional claims around the Klondike property. The claims have been filed with the Bureau of Land Management.

Klondike demonstrates exceptional tellurium grades. Tellurium, used in high-efficiency cadmium telluride (Cd-Te) solar panels, next-generation lithium-ion batteries and thermoelectric devices to change heat into energy, is an essential element for the world’s transition to green energy.

The Klondike property was a top tellurium prospect owned previously by First Solar Inc., one of the world’s largest solar panel producers. First Solar terminated its worldwide raw materials exploration program in 2012 and sold the property to Colorado Klondike LLC, which optioned the project to First Tellurium. Colorado Klondike, led by First Solar’s former Exploration Manager in North America, is managing the upcoming exploration program.

The Colorado Geological Survey (“CGS”), in partnership with the Colorado School of Mines, reported on First Solar’s exploration at Klondike in 2015, noting: “Surface sampling by First Solar, Inc. in 2006 found very high tellurium grades of up to 3.3% (33,000 ppm), along with locally high gold grades. Tellurium grades at Klondike were the highest encountered in the company’s nationwide exploration program.”

Market Outlook

First Tellurium in spring 2023 referenced recent forecasts by the International Energy Agency (“IEA”) pointing to rapid growth in solar photovoltaic (solar PV) deployment worldwide. According to the agency, solar PV installations will generate more power by 2027 than any other energy source, including coal, natural gas and hydro. To meet this demand, consumption of both silver and tellurium, key components of solar panels, is expected to surge in coming years.

Chen Lin, founder of Lin Asset Management, has written in his investment newsletter for clients that solar PV is now the largest industrial usage of silver. He said that in 2022 solar PV production used about 12% of total silver demand, or about 120 million ounces of silver. Lin expects this number to rise dramatically in the coming years, and that is likely to lead to silver supply deficits for decades to come.

Lin points out that solar power is now the cheapest source of energy in many parts of the world and that all forecasts point to dramatic expansion of solar PV in the coming two decades. Conservative estimates forecast 300 gigawatts of solar PV production by 2027, up from the current level of about 200 gigawatts.

Management Team

Tyrone Docherty is President, Director and CEO of First Tellurium Corp. He previously served as President and CEO of Quinto Mining Inc. With limited resources in a difficult market environment, he raised more than $30 million and advanced its Quebec iron ore property to a viable project. Quinto later sold for $175 million. From 2012 to 2018, he was Director and Chairman of Mason Graphite Inc. He has worked in the financial and minerals markets for more than 30 years.

Tony Fogarassy, M.Sc. LL.M., is Chairman of First Tellurium Corp. He is a lawyer and a geologist. His extensive legal and technical expertise includes minerals, oil and gas, coal and renewable energy projects and environmental and aboriginal/indigenous law in North America, Africa and Asia. He graduated as gold medalist in geological sciences from the University of British Columbia and in law from the London School of Economics.

For more information, visit the company’s website at www.FirstTellurium.com.

NOTE TO INVESTORS: The latest news and updates relating to FSTTF are available in the company’s newsroom at https://ibn.fm/FSTTF

• Legislation presented to Congress calls for the United States government to develop and adopt near-term quantum computing – some within 24 months or less for developing and deploying demos, proofs of concepts, and pilots
• Global government spending on quantum application development is expected to reach $36 billion during 2023
• D-Wave offers quantum solutions to help government and public sector develop applications that can solve important optimization problems

Recent legislation presented to Congress calls for the United States government to develop and adopt near-term quantum computing applications to solve complex public sector optimization problems, which could include electrical grid resilience, optimization of ports, global supply chain issues, emergency management and response, infrastructure, and telecommunication networks.  D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, has the technology necessary to develop these applications today for the optimization problems faced by the government and the public sector.

“The country is at a unique inflection point for U.S. quantum policy. To date, the U.S. National Quantum Strategy has not prioritized application development, but legislation before Congress has shifted that mindset,” said Dr. Alan Baratz, CEO of D-Wave (https://ibn.fm/pPYnJ). “D-Wave stands ready to collaborate with the U.S. government to build near-term quantum applications to help meet current and future public sector needs.”

The National Defense Authorization Act (“NDAA”) and the FY24 Energy and Water Appropriations bill, currently in the House of Representatives, advance policies that include developing near-term quantum applications. These represent an important shift in the government’s mindset about quantum, which had previously been focused on longer-term gate-model quantum solutions. The NDAA and Appropriation bills explicitly call for policies that include all viable quantum computing systems – including quantum annealing, gate-model, and quantum-hybrid technologies (quantum plus classical computing applications). The current legislation also includes an aggressive timeframe of 24 months or less for developing and deploying demos, proofs of concepts, and pilots.

Three other pieces of legislation regarding quantum are currently at various stages of the approval process. The Quantum Sandbox bill, presented in April 2023, calls for quantum and quantum-hybrid development and is proposed to amend the National Quantum Initiative Act to establish a public-private partnership for near-term application development and acceleration (https://ibn.fm/rV4iq). Additionally, the Wildfire Tech DEMO Act seeks quantum technology for wildfire response (https://ibn.fm/B2jCI), and the Quantum Practice Act calls for quantum technology use for modeling and simulations (https://ibn.fm/FNoQP).

All of the legislation supporting the use of quantum technology comes at a time when global government spending on quantum application development is increasing and is expected to reach $36 billion by the end of the year (https://ibn.fm/o7Rx2). Originally enacted in December 2018, the National Quantum Initiative Act is scheduled for reauthorization this year.

D-Wave, the world’s first commercial supplier of quantum computing solutions, is already providing solutions to its broad portfolio of commercial and government customers in areas such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection, and financial modeling, using the company’s quantum annealing technology. Companies, including Volkswagen, Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, Accenture, BBVA, NEC Corporation, Pattison Food Group Ltd., DENSO, and Lockheed Martin, are contributing to the company’s use cases through its collection of client success stories (https://ibn.fm/6HH95).

D-Wave stands ready to execute on the government’s shift to build near-term quantum applications with technology uniquely suited for solving the problems currently faced by the government and public sector’s optimization problems.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, which are subject to a number of risks. Forward-looking statements in this article include, but are not limited to, statements regarding the release and performance of the Advantage2 processor. We cannot assure you that the forward-looking statements in this article will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; customer acceptance of our products and services; and the uncertainties and factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form S-1 filed by the company with the SEC on February 13, 2023, as well as factors associated with companies, such as D-Wave, that are engaged in the business of quantum computing, including anticipated trends, growth rates, and challenges in those businesses and in the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; changes in applicable laws and regulations; the effect of pandemics, geopolitical events, natural disasters, wars, or terrorist acts on our business or the economy in general; and the impact of inflation. Furthermore, if the forward-looking statements contained in this article prove to be inaccurate, the inaccuracy may be material. In addition, you are cautioned that past performance may not be indicative of future results. In light of the significant uncertainties in these forward-looking statements, you should not place undue reliance on these statements in making an investment decision or regard these statements as a representation or warranty by any person we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this article represent our views as of the date of this article. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this article.

• Data is one of the most valuable and critical assets for today’s businesses, but with cyber-attacks on the rise it can quickly become one of their greatest liabilities
• Alarming statistics reveal that the number of security executives reporting security incidents in software-as-a-service environments surged from 43% to 55% over the past two years, with data leakage as the most common type of security incident, followed by malicious apps, data breaches, and ransomware
• Amid the current climate of ongoing data breach news, Data443 Risk Mitigation aims to cement its position as the provider of “All Things Data Security” by continuing to upgrade its product offering, securing new clients, and long-term customer renewals

“We are proud to be entrusted with our customer’s data, especially given the growing legal and regulatory risks within this environment of continuous data breaches,” said Jason Remillard, CEO and founder of Data443 Risk Mitigation (OTC: ATDS). “Our strength in Enhanced File Transfer/Managed File Transfer (EFT/MFT) with some of the world’s largest fintech enterprises positions Data443 to continue growing relationships in fintech and beyond as more enterprises leverage the public cloud for scale, cost savings, and disaster recovery. The company announced its latest product update—the addition of antivirus and ransomware protection to its EFT/MFT solution (https://ibn.fm/0gH0j).

As a data security and privacy software company, Data443 Risk Mitigation prides itself on securely processing thousands of sensitive data files per hour for its clients across the globe. The role of computer data continues to grow exponentially, enabling everyone – individuals, businesses, governments, schools, hospitals, and everything else in modern society to be more efficient. Entire businesses and sectors have launched to service the needs of processing and securing data. But in today’s digital business environment, data is also a massive target for cybercriminals. In the past, thieves used to break into bank vaults – now, they are attacking the cloud from anywhere in the world with an internet connection. The cloud has become the new target where the gold bullion of the new age – our data – is stored (https://ibn.fm/uL7yq).

A recent report shows that over 55% of security executives reported a security incident in their software-as-a-service environment over the last two years, marking a 12% surge from the previous year. The study, which surveyed 1,130 IT leaders, demonstrates that data leakage (or the unauthorized transmission of data from an organization to any external source) is the most common type of security incident (58%), followed by malicious apps (47%), data breaches (41%) and ransomware (40%).

Alarming statistics reveal another worrisome trend. More than half of respondents (58%) reported that their current SaaS security solutions cover only 50% or less of their SaaS applications, turning the spotlight on the growing need for robust security measures and increased awareness of the vulnerabilities the businesses open themselves to with the expanding SaaS landscape (https://ibn.fm/jvmJD).

As a data security and privacy software company, Data443 Risk Mitigation aims to tackle these challenges head-on. The company recently announced the enhancement of its Data Placement Manager (“DPM”), an Enhanced File Transfer/Managed File Transfer (EFT/MFT) solution, with antivirus and ransomware protection additions powered by the company’s Ransomware Recovery Manager (“RRM”), which was named “Best for Inexpensive Protection” and “Best for Kiosks” by PC Mag. In a bid to enhance its data security and protection capabilities and cyber threat intelligence (“CTI”) services, the company has recently closed a definitive agreement to acquire select assets from Cyren Ltd., which includes Cyren’s proprietary technology and intellectual property related to threat intelligence, URL categorization, and email security.

The company appears to be on a winning streak amid a recent surge of customer renewals and additional contract wins following the recent influx of fintech clients committing to the company’s EFT/MFT solution. With clients experiencing as much as 99.999% uptime, equivalent to an average of fewer than six minutes of downtime per year, Data443 Risk Mitigation appears committed to achieving its mission to become the go-to provider for “All Things Data Security.”

Data443 Risk Mitigation, Inc. (ATDS) Investor Relations
Matthew Abenante
ir@data443.com 
919-858-6542

For more information, visit the company’s website at www.Data443.com.

NOTE TO INVESTORS: The latest news and updates relating to ATDS are available in the company’s newsroom at https://ibn.fm/ATDS

• Genprex recently announced that its lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities in the Phase 1 portion of its Acclaim-1 clinical trial
• The Phase 1 clinical data were added to by the release of a new patient video highlighting a patient’s experience with REQORSA. This patient has now been on the Acclaim-1 trial without disease progression for one year
• The Safety Review Committee approved the advancement of the Acclaim 1 clinical trial to the Phase 2 expansion portion of the trial

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with diabetes and cancer, recently disclosed favorable preliminary clinical data from the Phase 1 portion of its Acclaim-1 clinical trial. During the study, Genprex’s lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities. In addition, the company reported preliminary evidence of efficacy in the phase 1 portion of the study.

“We are encouraged by the favorable safety profile of REQORSA, as well as the preliminary efficacy data we have observed. These data supported the Safety Review Committee’s approval to advance to the Phase 2 expansion portion of the clinical trial which we expect to begin in the third quarter,” said Mark Berger, MD, Chief Medical Officer at Genprex (https://ibn.fm/miTxk).

The Phase 1 clinical data were added to by the recent release of a new patient video featuring a non-small cell lung cancer (“NSCLC”) patient from the Phase 1 portion of the study. The patient highlighted in the video achieved a Partial Response and experienced extended Progression Free Survival (“PFS”). She described her positive experience taking REQORSA. This patient has now been on the Acclaim-1 trial without disease progression for one year.

The patient’s positive experience has been described as encouraging, mainly because she could continue working full-time while participating in the clinical trial. She only experienced minor side effects from using the lead drug candidate. This is particularly significant since NSCLC is ranked as the most common type of lung cancer, accounting for about 82% of all cases. In addition, the overall survival rate for patients with advanced levels of the condition is alarmingly low, with a five-year survival rate for patients with distant spread standing at 7% (https://ibn.fm/85dk7).

“While on REQORSA treatment, my doctor noted that the lung cancer lesions have not grown, and there is no new growth,” noted the NSCLC patient.

“I believe the REQORSA treatment has benefited my life and has increased my time,” she added.

The Safety Review Committee (“SRC”) noted that there were no Dose Limiting Toxcities (“DLTs”) during the Phase 1 trial and approved the advancement of the Acclaim-1 clinical trial to the Phase 2 expansion portion of the trial. The approval is a significant milestone in REQORSA’s development program, and now positions REQORSA as a Phase 2 clinical trial asset.

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX